Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
direct thrombin inhibitor |
| gptkbp:antidote |
gptkb:idarucizumab
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2008 |
| gptkbp:ATCCode |
B01AE07
|
| gptkbp:bioavailability |
6.5%
|
| gptkbp:brand |
gptkb:Pradaxa
|
| gptkbp:CASNumber |
211914-51-1
|
| gptkbp:category |
DOAC (direct oral anticoagulant)
NOAC (novel oral anticoagulant) |
| gptkbp:contraindication |
active pathological bleeding
mechanical heart valve |
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
|
| gptkbp:discoveredBy |
gptkb:Boehringer_Ingelheim
|
| gptkbp:eliminationHalfLife |
12-17 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:form |
capsule
150 mg 75 mg 110 mg |
| gptkbp:hasMolecularFormula |
C34H41N7O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
dabigatran
|
| gptkbp:interactsWith |
gptkb:rifampin
gptkb:ketoconazole P-glycoprotein inhibitors |
| gptkbp:KEGGID |
D08141
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
direct inhibition of thrombin (factor IIa)
|
| gptkbp:MedlinePlusID |
a610024
|
| gptkbp:metabolism |
not metabolized by CYP450
|
| gptkbp:patentExpired |
2023 (US)
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
35%
|
| gptkbp:PubChem_CID |
448119
CHEMBL1175 DB06695 |
| gptkbp:riskFactor |
not recommended in patients with prosthetic heart valves
risk of spinal/epidural hematoma with neuraxial anesthesia increased risk of bleeding with P-gp inhibitors may cause dyspepsia not recommended in severe renal impairment |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
bleeding
gastrointestinal upset |
| gptkbp:UNII |
2XTZ996338
|
| gptkbp:usedFor |
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis treatment of pulmonary embolism |
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|